Neuropsychological change in schizophrenia after 6 weeks of clozapine

被引:41
作者
Purdon, SE
Labelle, A
Boulay, L
机构
[1] Univ Alberta, Dept Psychiat, Edmonton, AB, Canada
[2] Univ Ottawa, Dept Psychiat, Ottawa, ON K1N 6N5, Canada
[3] Royal Ottawa Hosp, Schizophrenia Program, Ottawa, ON K1Z 7K4, Canada
[4] Carleton Univ, Ottawa, ON K1S 5B6, Canada
关键词
clozapine; cognition; neuroleptic; neuropsychology; schizophrenia;
D O I
10.1016/S0920-9964(00)00101-8
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Neuropsychological change after 6 weeks of clozapine treatment was examined in 18 treatment-refractory patients to test anticipated domain-specific cognitive improvements. The first aim of this study was to test the assumption that increased homogeneity of sample and treatment would yield an experimental design with sufficient sensitivity to detect general intellectual changes with clozapine that were not apparent in one previous investigation. The second aim was to test predictions derived from a domain-specific review of all other investigations with clozapine suggesting salient gains on tests sensitive to motor and mental speed, visual spatial manipulation, and new learning of verbal material. The results showed that the comprehensive neuropsychological test battery was sensitive to general cognitive changes with clozapine, and supported the hypothesized domain-specific gains on tests of motor and mental speed, visual spatial manipulation and new verbal learning. Novel gains were also apparent on tests of new learning with nonverbal material. The results are discussed in relation to aspects of experimental design necessary for the evaluation of prospective medication-induced changes in cognitive skill, particularly in future investigations designed to differentiate between second-generation antipsychotic medications. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:57 / 67
页数:11
相关论文
共 37 条
[11]   IMPROVEMENT IN COGNITIVE FUNCTIONS AND PSYCHIATRIC-SYMPTOMS IN TREATMENT-REFRACTORY SCHIZOPHRENIC-PATIENTS RECEIVING CLOZAPINE [J].
HAGGER, C ;
BUCKLEY, P ;
KENNY, JT ;
FRIEDMAN, L ;
UBOGY, D ;
MELTZER, HY .
BIOLOGICAL PSYCHIATRY, 1993, 34 (10) :702-712
[12]   The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients [J].
Hoff, AL ;
Faustman, WO ;
Wieneke, M ;
Espinoza, S ;
Costa, M ;
Wolkowitz, O ;
Csernansky, JG .
NEUROPSYCHOPHARMACOLOGY, 1996, 15 (04) :361-369
[13]  
Kay S.R., 1992, Positive and Negative Syndrome Scale: Manual
[14]   The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis [J].
Keefe, RSE ;
Silva, SG ;
Perkins, DO ;
Lieberman, JA .
SCHIZOPHRENIA BULLETIN, 1999, 25 (02) :201-222
[15]  
KOH SD, 1978, LANGUAGE COGNITION S, P55
[16]   SCHIZOPHRENIA WITH GOOD AND POOR OUTCOME .3. NEUROLOGICAL SOFT SIGNS, COGNITIVE IMPAIRMENT AND THEIR CLINICAL-SIGNIFICANCE [J].
KOLAKOWSKA, T ;
WILLIAMS, AO ;
JAMBOR, K ;
ARDERN, M .
BRITISH JOURNAL OF PSYCHIATRY, 1985, 146 (APR) :348-357
[17]   PERFORMANCE OF SCHIZOPHRENIC-PATIENTS ON TESTS SENSITIVE TO LEFT OR RIGHT FRONTAL, TEMPORAL, OR PARIETAL FUNCTION IN NEUROLOGICAL PATIENTS [J].
KOLB, B ;
WHISHAW, IQ .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1983, 171 (07) :435-443
[18]   Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2 [J].
Lee, H ;
Trainer, AH ;
Friedman, LS ;
Thistlethwaite, FC ;
Evans, MJ ;
Ponder, BAJ ;
Venkitaraman, AR .
MOLECULAR CELL, 1999, 4 (01) :1-10
[19]  
LEE MA, 1994, J CLIN PSYCHIAT, V55, P82
[20]  
Medalia A, 1988, Arch Clin Neuropsychol, V3, P249, DOI 10.1016/0887-6177(88)90018-2